With the failure of AbbVie’s emraclidine in two mid-stage trials, Bristol Myers Squibb’s Cobenfy is 'sole muscarinic winner.' ...
Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...
Leerink upgrades Bristol-Myers Squibb with an increased price target and strong sales projections for Cobenfy and milvexian, ...
Leerink Partners raised its target for Bristol-Myers Squibb from $55 to $73, citing optimism for the company's products Cobenfy (KarXT) and milvexian, a novel blood thinner. Similarly, BMO Capital ...
Leerink Partners raised its target for Bristol-Myers Squibb from $55 to $73, citing optimism for the company's products Cobenfy (KarXT) and milvexian, a novel blood thinner. Similarly, BMO Capital ...
The shocking failure of AbbVie’s emraclidine has investors questioning the Big Pharma’s long-term neuroscience strategy, ...
AbbVie Inc.'s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., analysts said.
Portfolio Receipts growth of 15% to $735 million; Royalty Receipts growth of 15%Net cash provided by operating activities of $704 millionCapital ...
BMS got its hands on KarXT through its $14 billion buyout of Karuna Therapeutics last December. According to analysts at William Blair, Cobenfy in the U.S. could achieve sales of roughly $2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback